WO2005123945A3 - Epigenetic markers for the treatment of breast cancer - Google Patents

Epigenetic markers for the treatment of breast cancer Download PDF

Info

Publication number
WO2005123945A3
WO2005123945A3 PCT/EP2005/006713 EP2005006713W WO2005123945A3 WO 2005123945 A3 WO2005123945 A3 WO 2005123945A3 EP 2005006713 W EP2005006713 W EP 2005006713W WO 2005123945 A3 WO2005123945 A3 WO 2005123945A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
treatment
epigenetic markers
markers
status
Prior art date
Application number
PCT/EP2005/006713
Other languages
French (fr)
Other versions
WO2005123945A2 (en
Inventor
Ralf Lesche
Anne Fassbender
Klaus Juenemann
John Foekens
John W M Martens
Sabine Maier
Inko Nimmrich
Thomas Koenig
Shan Wang-Gohrke
Original Assignee
Epigenomics Ag
Ralf Lesche
Anne Fassbender
Klaus Juenemann
John Foekens
John W M Martens
Sabine Maier
Inko Nimmrich
Thomas Koenig
Shan Wang-Gohrke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenomics Ag, Ralf Lesche, Anne Fassbender, Klaus Juenemann, John Foekens, John W M Martens, Sabine Maier, Inko Nimmrich, Thomas Koenig, Shan Wang-Gohrke filed Critical Epigenomics Ag
Publication of WO2005123945A2 publication Critical patent/WO2005123945A2/en
Publication of WO2005123945A3 publication Critical patent/WO2005123945A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides novel epigenetic markers with utility in the treatment of breast cancer. The markers enable the prediction of nodal status, estrogen receptor status and progesterone receptor status in breast cancer patients. Accurate prediction and monitoring of said parameters enables the clinician to recommend suitable therapies.
PCT/EP2005/006713 2004-06-21 2005-06-21 Epigenetic markers for the treatment of breast cancer WO2005123945A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04090244 2004-06-21
EP04090244.7 2004-06-21

Publications (2)

Publication Number Publication Date
WO2005123945A2 WO2005123945A2 (en) 2005-12-29
WO2005123945A3 true WO2005123945A3 (en) 2006-03-23

Family

ID=35057042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006713 WO2005123945A2 (en) 2004-06-21 2005-06-21 Epigenetic markers for the treatment of breast cancer

Country Status (1)

Country Link
WO (1) WO2005123945A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114921544A (en) 2005-04-15 2022-08-19 Epi基因组股份公司 Methods and nucleic acids for analyzing cell proliferative disorders
US20090317810A1 (en) * 2006-04-17 2009-12-24 Epigenomics Ag Methods and nucleic acids for the detection of colorectal cell proliferative disorders
EP2484778A3 (en) * 2006-04-17 2012-10-10 Epigenomics AG Methods and nucleic acids for the detection of colorectal cell proliferative disorders
ES2546182T3 (en) * 2006-07-21 2015-09-21 Epigenomics Ag Methods and kits for methylation analysis in colorectal cell proliferative disorders
EP2115165B1 (en) * 2007-01-19 2012-03-14 Epigenomics AG Methods and nucleic acids for analyses of cell proliferative disorders
RU2492243C2 (en) * 2007-09-17 2013-09-10 Конинклейке Филипс Электроникс Н.В. Method of analysis of mammary gland cancerous diseases
WO2009156584A1 (en) * 2008-06-24 2009-12-30 Valtion Teknillinen Tutkimuskeskus Assessing risk of metastases and/or ddfs of patients with neoplasms, screening of patients responding to cancer therapy and such therapy
RU2011135955A (en) * 2009-01-30 2013-03-10 Конинклейке Филипс Электроникс Н.В. METHODS FOR CLASSIFICATION OF BREAST TUMORS WITH DIVIDING
JP5986746B2 (en) * 2009-06-30 2016-09-06 シスメックス株式会社 Method, molecular marker and kit for determining the presence or absence of cells derived from epithelial cancer in a biological sample
EP2505665A1 (en) * 2011-03-31 2012-10-03 Queen Mary And Westfield College, University Of London Cancer markers
AU2016363830C1 (en) * 2015-12-04 2022-03-24 Centre National De La Recherche Scientifique Promoters and uses thereof
WO2018048354A1 (en) * 2016-09-07 2018-03-15 Agency For Science, Technology And Research A method of identifying risk of cancer and therapeutic options
WO2020013355A1 (en) * 2018-07-10 2020-01-16 서울대학교산학협력단 Composition for predicting prognosis of malignant phyllodes tumor and kit comprising same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20030138783A1 (en) * 2001-01-26 2003-07-24 Saraswati Sukumar Aberrantly methylated genes as markers of breast malignancy
WO2004035803A2 (en) * 2002-10-01 2004-04-29 Epigenomics Ag Method and nucleic acids for the treatment of breast cell proliferative disorders
WO2005040421A2 (en) * 2003-10-17 2005-05-06 Martin Widschwendter Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138783A1 (en) * 2001-01-26 2003-07-24 Saraswati Sukumar Aberrantly methylated genes as markers of breast malignancy
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2004035803A2 (en) * 2002-10-01 2004-04-29 Epigenomics Ag Method and nucleic acids for the treatment of breast cell proliferative disorders
WO2005040421A2 (en) * 2003-10-17 2005-05-06 Martin Widschwendter Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
BURGER ANGELIKA M ET AL: "Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas", ONCOGENE, vol. 16, no. 19, 14 May 1998 (1998-05-14), pages 2459 - 2467, XP002349668, ISSN: 0950-9232 *
FACKLER MARY JO ET AL: "DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 20 DEC 2003, vol. 107, no. 6, 20 December 2003 (2003-12-20), pages 970 - 975, XP008038883, ISSN: 0020-7136 *
GITAN RAAD S ET AL: "Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 12, no. 1, January 2002 (2002-01-01), pages 158 - 164, XP002208051, ISSN: 1088-9051 *
HAMELERS I H L ET AL: "Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells.", ENDOCRINE-RELATED CANCER. JUN 2003, vol. 10, no. 2, June 2003 (2003-06-01), pages 331 - 345, XP002349676, ISSN: 1351-0088 *
KATO MITSUO: "Regulation of the mac25 gene and its application for cancer treatment", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 8, no. Supplement 1, 2001, & 6TH WORLD CONGRESS ON ADVANCES IN ONCOLOGY, AND THE 4TH INTERNATIONAL SYMPOSIUM ON MOLECULAR MEDICIN; HERSONISSOS, CRETE, GREECE; OCTOBER 18-20, 2001, pages S64, XP009055496, ISSN: 1107-3756 *
LANDBERG GORAN ET AL: "Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors", ONCOGENE, vol. 20, no. 27, 14 June 2001 (2001-06-14), pages 3497 - 3505, XP002349667, ISSN: 0950-9232 *
LAPIDUS R G ET AL: "The loss of estrogen and progesterone receptor gene expression in human breast cancer.", JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA. JAN 1998, vol. 3, no. 1, January 1998 (1998-01-01), pages 85 - 94, XP002349675, ISSN: 1083-3021 *
MEHROTRA JYOTI ET AL: "Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 MAR 2004, vol. 10, no. 6, 15 March 2004 (2004-03-15), pages 2052 - 2057, XP002349665, ISSN: 1078-0432 *
MIELNICKI L M ET AL: "Genes, chromatin, and breast cancer: an epigenetic tale.", JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA. APR 2001, vol. 6, no. 2, April 2001 (2001-04-01), pages 169 - 182, XP002349670, ISSN: 1083-3021 *
MÜLLER H M ET AL: "DNA methylation in serum of breast cancer patients: an independent prognostic marker", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 63, no. 22, 15 November 2003 (2003-11-15), pages 7641 - 7645, XP002317189, ISSN: 0008-5472 *
OH YOUNGMAN ET AL: "Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 48, 1996, pages 30322 - 30325, XP002349669, ISSN: 0021-9258 *
SETH ARUN ET AL: "Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.", ANTICANCER RESEARCH, vol. 23, no. 3A, 2003, pages 2043 - 2052, XP009055494, ISSN: 0250-7005 *
SPRENGER C C ET AL: "INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1 (IGFBP-RP1) IS A POTENTIAL TUMOR SUPPRESSOR PROTEIN FOR PROSTATE CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 15 May 1999 (1999-05-15), pages 2370 - 2375, XP002939648, ISSN: 0008-5472 *
SWISSHELM K ET AL: "ENHANCED EXPRESSION OF AN INSULIN GROWTH FACTOR-LIKE BINDING PROTEIN (MAC25) IN SENESCENT HUMAN MAMMARY EPITHELIAL CELLS AND INDUCED EXPRESSION WITH RETINOIC ACID", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 92, May 1995 (1995-05-01), pages 4472 - 4476, XP000770659, ISSN: 0027-8424 *
WIDSCHWENDTER M ET AL: "DNA methylation profiles in breast cancer - relation to hormone receptors and role in response to adjuvant endocrine treatment", EJC SUPPLEMENTS, vol. 2, no. 1, February 2004 (2004-02-01), & 3RD INTERNATIONAL CONFERENCE AND 9TH ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF CANCER CHEMOPRE; ST. GALLEN, SWITZERLAND; FEBRUARY 12-14, 2004, pages 50, XP009055498, ISSN: 1359-6349 *
WIDSCHWENDTER MARTIN ET AL: "Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen", CANCER RESEARCH, vol. 64, no. 11, 1 June 2004 (2004-06-01), pages 3807 - 3813, XP002349664, ISSN: 0008-5472 *
WIDSCHWENDTER MARTIN ET AL: "DNA methylation and breast carcinogenesis.", ONCOGENE. 12 AUG 2002, vol. 21, no. 35, 12 August 2002 (2002-08-12), pages 5462 - 5482, XP009001821, ISSN: 0950-9232 *
WILSON HEATHER-MARIE P ET AL: "Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism", CELL GROWTH AND DIFFERENTIATION, vol. 13, no. 5, May 2002 (2002-05-01), pages 205 - 213, XP002349666, ISSN: 1044-9523 *
YEE D ET AL: "Crosstalk between the insulin-like growth factors and estrogens in breast cancer.", JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA. JAN 2000, vol. 5, no. 1, January 2000 (2000-01-01), pages 107 - 115, XP002349677, ISSN: 1083-3021 *

Also Published As

Publication number Publication date
WO2005123945A2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2005123945A3 (en) Epigenetic markers for the treatment of breast cancer
Kaplan et al. Primer on the metabolic bone diseases and disorders of mineral metabolism
EP1703283A4 (en) Clinical examination analyzing device, clinical examination analyzing method, and program for allowing computer to execute the method
MY185858A (en) Specific binding proteins and uses thereof
IL180251A0 (en) Methods and reagents for the treatment of metabolic disorders
AU2005214925A8 (en) Network and methods for integrating individualized clinical test results and nutritional treatment
EP2069909A4 (en) Strategy for providing query results based on analysis of user intent
EP1781328A4 (en) Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
EP1793858A4 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2012009453A3 (en) Non-invasive monitoring of physiological conditions
WO2010017515A3 (en) Breast cancer specific markers and methods of use
SI1827441T1 (en) Combinations for the treatment of diseases involving cell proliferation
EP1937845A4 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
GB0418542D0 (en) Integrated biosensor and simulation system for diagnosis and therapy
ZA200701277B (en) Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
WO2012076553A3 (en) Biomarkers and parameters for hypertensive disorders of pregnancy
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2009061800A3 (en) Methods and compositions for diagnostic use in cancer patients
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2009085271A3 (en) Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
GB0423885D0 (en) Blood analysis
EP1793857A4 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
WO2010009129A3 (en) Methods of treating autoimmune diseases using cd4 antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase